DMD

After agreeing to cover Sarepta Therapeutics Inc (NASDAQ: SRPT)’s controversial Duchenne muscular dystrophy drug Exondys 51, insurer Aetna Inc (NYSE: AET) has released a new clinical policy bulletin describing the conditions under which it deems the drug medically necessary. Aetna now...

Back on October 6, Duchenne Muscular Dystrophy (DMD) treatment advocate Jenn McNary announced on Twitter that Humana Inc (NYSE: HUM) had approved 100 percent coverage for a patient wanting access to Sarepta Therapeutics Inc (NASDAQ: SRPT) muscular dystrophy drug eteplirsen - marketed as EXONDYS...

Shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) soared more than 80 percent higher on Friday. The company confirmed that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended the renewal of the company's therapy called Translarna (ataluren...

Leerink's Joseph Schwartz felt it prudent to take a deep dive into Sarepta Therapeutics Inc's (NASDAQ: SRPT) EXONDYS 51, the company's therapy for the treatment of Duchenne muscular dystrophy (DMD). There are three reasons investors should take a "more cautious view" on...

Shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) soared higher by nearly 90 percent early Friday morning after the company announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended the renewal of the company's therapy called...

Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) fell about 5 percent Friday after Anthem Blue Cross said the clinical benefit of treatment for DMD (Duchenne Muscular Dystrophy) with the company's eteplirsen (Exondys 51), including improved motor function, has "not been demonstrated....

Sarepta Therapeutics Inc (NASDAQ: SRPT) forged a deal with Summit Therapeutics PLC (ADR) (NASDAQ: SMMT) to develop its utrophin pipeline in exchange for European rights and a Latin America option. Summit's stock soared higher by more than 100 percent following the announcement, but analysts...

Sarepta Therapeutics Inc (NASDAQ: SRPT) and Summit Therapeutics plc (NASDAQ: SMMT) reached an exclusive license and collaboration agreement. As a result, Sarepta has been granted rights in Europe, and Turkey apart from the Commonwealth of Independent States to Summit's utrophin modulator...

Sarepta Therapeutics Inc (NASDAQ: SRPT) revealed that it dosed first patient in final stage clinical study of SRP-4045 and SRP-4053 for treatment of Duchenne Muscular Dystrophy Amenable to exon 45 or 53 skipping. The company indicated the third stage trial, ESSENCE, is a double-blind, placebo-...

It looks like Sarepta Therapeutics Inc (NASDAQ: SRPT)'s Eteplirsen may not be out of the woods just yet.  A letter from U.S. Food & Drug Administration Commissioner Robert Califf is calling for the drug's latest study to be retracted. The 13-page memo is dated Friday,...

Sarepta Therapeutics Inc (NASDAQ: SRPT) hosted a conference call Tuesday to discuss its newly approved drug, Exondys 51 (eteplirsen) injection, which happens to be the first drug approved to treat patients with Duchenne muscular dystrophy (DMD). Sarepta said Exondys 51 will be available in a...

Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) soared higher by more than 80 percent Monday and hit a new 52-week high of $56.18. Traders turned uber-bullish on the stock after the U.S. Food and Drug Administration granted an accelerated approval for its Duchenne Muscular Dystrophy (DMD) drug...

PTC Therapeutics, Inc. (NASDAQ: PTCT) shares received a big boost Monday, thanks to positive tidings received by Sarepta Therapeutics Inc. (NASDAQ: SRPT). The latter received FDA's accelerated approval for eteplirsen for treating exon 51 skipping amenable Duchenne's muscular dystrophy....

Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) spiked higher by around 20 percent Thursday morning after The Street's biotech expert Adam Feuerstein penned an article titled "Why Sarepta Can Ultimately Win FDA Drug Approval." Shares of Sarepta were hard hit after a federal...